Your browser doesn't support javascript.
loading
AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells.
Pop, Oltin-Tiberiu; Geng, Anne; Flint, Emilio; Singanayagam, Arjuna; Ercan, Caner; Possamai, Lucia; Patel, Vishal C; Kuenzler, Patrizia; Meier, Marie-Anne; Soysal, Savas; Hruz, Petr; Kollmar, Otto; Tatham, Kate C; Ward, Josie K; Müllhaupt, Beat; Weber, Achim; Wendon, Julia; Niess, Jan Hendrik; Heim, Markus; Semela, David; Weston, Christopher; Antoniades, Charalambos G; Terracciano, Luigi Maria; Triantafyllou, Evangelos; Brenig, Robert G; Bernsmeier, Christine.
Afiliação
  • Pop OT; Medical Research Centre and Division of Gastroenterology and Hepatology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Institute of Immunobiology, Medical Research Centre, Cantonal Hospital St Gallen, St Gallen, Switzerland.
  • Geng A; Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Flint E; Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Singanayagam A; Institute of Liver Studies, King's College Hospital, King's College London, London, United Kingdom; Hepatology Department, St Mary's Hospital, Imperial College London, London, United Kingdom.
  • Ercan C; University Hospital, Basel, Institute of Pathology, Basel, Switzerland.
  • Possamai L; Hepatology Department, St Mary's Hospital, Imperial College London, London, United Kingdom.
  • Patel VC; Institute of Liver Studies, King's College Hospital, King's College London, London, United Kingdom; The Roger Williams Institute of Hepatology London, Foundation for Liver Research, London, United Kingdom & School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King'
  • Kuenzler P; Medical Research Centre and Division of Gastroenterology and Hepatology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
  • Meier MA; Department of Biomedicine, University of Basel, Basel, Switzerland; Gastroenterology and Hepatology, University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.
  • Soysal S; Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.
  • Hruz P; Department of Biomedicine, University of Basel, Basel, Switzerland; Gastroenterology and Hepatology, University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.
  • Kollmar O; Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.
  • Tatham KC; Section of Anaesthetics, Pain Medicine and Intensive Care Medicine, Department of Surgery and Cancer, Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Ward JK; Section of Anaesthetics, Pain Medicine and Intensive Care Medicine, Department of Surgery and Cancer, Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Müllhaupt B; Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
  • Weber A; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Wendon J; Institute of Liver Studies, King's College Hospital, King's College London, London, United Kingdom.
  • Niess JH; Department of Biomedicine, University of Basel, Basel, Switzerland; Gastroenterology and Hepatology, University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.
  • Heim M; Department of Biomedicine, University of Basel, Basel, Switzerland; Gastroenterology and Hepatology, University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.
  • Semela D; Medical Research Centre and Division of Gastroenterology and Hepatology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
  • Weston C; Centre for Liver Research and National Institute for Health Research, Biomedical Research Unit, University of Birmingham, Birmingham, United Kingdom.
  • Antoniades CG; Institute of Liver Studies, King's College Hospital, King's College London, London, United Kingdom; Hepatology Department, St Mary's Hospital, Imperial College London, London, United Kingdom.
  • Terracciano LM; University Hospital, Basel, Institute of Pathology, Basel, Switzerland.
  • Triantafyllou E; Hepatology Department, St Mary's Hospital, Imperial College London, London, United Kingdom.
  • Brenig RG; Medical Research Centre and Division of Gastroenterology and Hepatology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Biomedicine, University of Basel, Basel, Switzerland. Electronic address: robert.brenig@unibas.ch.
  • Bernsmeier C; Department of Biomedicine, University of Basel, Basel, Switzerland; Gastroenterology and Hepatology, University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland. Electronic address: c.bernsmeier@unibas.ch.
Cell Mol Gastroenterol Hepatol ; 16(1): 17-37, 2023.
Article em En | MEDLINE | ID: mdl-37004869
ABSTRACT
BACKGROUND &

AIMS:

AXL and MERTK expression on circulating monocytes modulated immune responses in patients with cirrhosis (CD14+HLA-DR+AXL+) and acute-on-chronic liver failure (CD14+MERTK+). AXL expression involved enhanced efferocytosis, sustained phagocytosis, but reduced tumor necrosis factor-α/interleukin-6 production and T-cell activation, suggesting a homeostatic function. Axl was expressed on murine airway in tissues contacting the external environment, but not interstitial lung- and tissue-resident synovial lining macrophages. Here, we assessed AXL expression on tissue macrophages in patients with cirrhosis.

METHODS:

Using multiplexed immunofluorescence we compared AXL expression in liver biopsies in cirrhosis (n = 22), chronic liver disease (n = 8), non-cirrhotic portal hypertension (n = 4), and healthy controls (n = 4). Phenotype and function of isolated primary human liver macrophages were characterized by flow cytometry (cirrhosis, n = 11; control, n = 14) ex vivo. Also, AXL expression was assessed on peritoneal (n = 29) and gut macrophages (n = 16) from cirrhotic patients. Regulation of AXL expression was analyzed in vitro and ex vivo using primary hepatic stellate cells (HSCs), LX-2 cells, and GAS6 in co-culture experiments.

RESULTS:

AXL was expressed on resident (CD68+) but not tissue-infiltrating (MAC387+) liver macrophages, hepatocytes, HSCs, or sinusoidal endothelial cells. Prevalence of hepatic CD68+AXL+ cells significantly decreased with cirrhosis progression (healthy, 90.2%; Child-Pugh A, 76.1%; Child-Pugh B, 64.5%; and Child-Pugh C, 18.7%; all P < .05) and negatively correlated with Model for End-Stage Liver Disease and C-reactive protein (all P < .05). AXL-expressing hepatic macrophages were CD68highHLA-DRhighCD16highCD206high. AXL expression also decreased on gut and peritoneal macrophages from cirrhotic patients but increased in regional lymph nodes. GAS6, enriched in the cirrhotic liver, appeared to be secreted by HSCs and down-regulate AXL in vitro.

CONCLUSIONS:

Decreased AXL expression on resident liver macrophages in advanced cirrhosis, potentially in response to activated HSC-secreted GAS6, suggests a role for AXL in the regulation of hepatic immune homeostasis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Estreladas do Fígado / Doença Hepática Terminal Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Estreladas do Fígado / Doença Hepática Terminal Idioma: En Ano de publicação: 2023 Tipo de documento: Article